Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Adeno-associated virus (AAV)-mediated gene therapy is under investigation as a therapeutic option for persons with hemophilia A. Efficacy and safety data include 3 years of follow-up after a single administration of AAV5-hFVIII-SQ. METHODS: We report durable efficacy, long-term safety, and clinical and biologic results in 15 adults with severe hemophilia A (factor VIII level, ≤1 IU per deciliter) who had received a single infusion of AAV5-hFVIII-SQ at various dose levels. We evaluated the factor VIII level, annualized rate of bleeding events, use of factor VIII, safety, expression kinetics, and biologic markers of AAV transduction for up to 3 years. RESULTS: vg per kilogram) had a median factor VIII expression of 13 IU per deciliter; the median annualized rate of bleeding events was 0, and the median use of factor VIII was reduced from 155.5 infusions to 0.5 infusions per year. Bleeding in target joints resolved in five of six participants. The factor VIII pharmacodynamic profiles reflected cellular turnover in the blood and molecular events leading to episomal DNA stabilization for persistent expression, findings that are consistent with previous observations in two model systems. Transgene-derived human factor VIII (hFVIII) protein activity mirrored native hFVIII in hemostatic ability. No inhibitor development, thromboses, deaths, or persistent changes in liver-function tests were observed. CONCLUSIONS: vg per kilogram of the gene therapy. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, NCT02576795; EudraCT number, 2014-003880-38.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 5 subjects across 3 trials experienced self-limited, vector-infusion reactions at doses of 2 × 1012−6 × 1013 vg/kg, characterized by fever, myalgias, and/or hypotension, which appear consistent with an innate immune response.141,150,152”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [150]
In the citing paper
“multiple HA and HB trials have demonstrated ≥10-fold variability in FVIII:C/FIX:C with the same vector and dose (Harrington et al., 2020, WFH Virtual Summit, conference).145,149,150,153”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [150]
In the citing paper
“Corticosteroids are the most commonly used agents to resolve transaminitis, however, its relationship with resolution by corticosteroids and T-cell response are not always clear as observed in a hemophilia A trial (28, 105).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [105]
Citations
Cites
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Definitions in hemophilia: communication from the SSC of the ISTH
Blanchette, V. S., Key, N. S., Ljung, L. R., Manco‐Johnson, M. J., van den Berg, H. M., & Srivastava, A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12672 · Cited by 761
Nucleotide sequence and organization of the adeno-associated virus 2 genome
Srivastava, A., Lusby, E. W., & Berns, K. I. (1983) · Journal of Virology · doi:10.1128/jvi.45.2.555-564.1983 · Cited by 721
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Self-citationAntioxidants reduce endoplasmic reticulum stress and improve protein secretion
Malhotra, J. D., Miao, H., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S. W., & Kaufman, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809677105 · Cited by 673
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Research works printed but not linked: 2
- Torres R, Patton K, Holcomb J, Zoog S, Russell C, Vettermann C. Characterization of AAV5-FVIII-SQ vector DNA in human blood by real-time and Droplet Digital PCR. Mol Ther 2019;27(4):Suppl 1:436-436.
- Fong S, Handyside B, Sihn C-R, et al. The potential for induction of ER stress response by an AAV5-based construct of B-domain deleted FVIII is dependent on the strength of the hepatic specific promoter. Mol Ther 2018;26(5):Suppl 1:375-376.
Cited by
Items 101–200 of 453
Sihn, C., Handyside, B., Liu, S., Zhang, L., Murphy, R., Yates, B., Xie, L. Y., Torres, R., Russell, C. B., O’neill, C. A., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.12.004 · Cited by 35
Self-citationXia, K., Wang, F., Lai, X., Dong, L., Luo, P., Zhang, S., Yang, C., Chen, H., Ma, Y., Huang, W., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100792 · Cited by 36
The Unusual Properties of the AAV Inverted Terminal Repeat
Berns, K. I. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.017 · Cited by 35
Prophylaxis for hemophilia A without inhibitors: treatment options and considerations
Valentino, L. A., & Khair, K. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1775576 · Cited by 33
Ahmed, H., Foster, R., & Otto, M. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101164 · Cited by 32
Delivering on the promise of gene therapy for haemophilia
Pipe, S. W. (2020) · Haemophilia · doi:10.1111/hae.14027 · Cited by 32
Haemophilia: factoring in new therapies
Fassel, H., & McGuinn, C. E. (2021) · British Journal of Haematology · doi:10.1111/bjh.17580 · Cited by 35
Preventing packaging of translatable P5-associated DNA contaminants in recombinant AAV vector preps
Brimble, M. A., Cheng, P.-H., Winston, S. M., Reeves, I. L., Souquette, A., Spence, Y., Zhou, J., Wang, Y.-D., Morton, C. L., Valentine, M., et al. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.008 · Cited by 30
O’Mahony, B., Dunn, A. L., Leavitt, A. D., Peyvandi, F., Ozelo, M. C., Mahlangu, J. N., Peerlinck, K., Wang, J., Lowe, G., Tan, C.-W., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.08.032 · Cited by 31
Self-citationWFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia
Cantore, A., & Naldini, L. (2020) · Haemophilia · doi:10.1111/hae.14056 · Cited by 33
Wu, Z., Xu, L., He, Y., Xu, K., Chen, Z., Moqbel, S. A. A., Ma, C., Jiang, L., Ran, J., Wu, L., et al. (2020) · Aging · doi:10.18632/aging.202252 · Cited by 33
Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective
Tomeo, F., Mariz, S., Brunetta, A. L., Stoyanova-Beninska, V. V., Penttilä, K., & Magrelli, A. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14838 · Cited by 34
Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?
Ellsworth, P., & Ma, A. L. (2021) · Hematology · doi:10.1182/hematology.2021000253 · Cited by 30
Clinical Pharmacology Considerations on Recombinant Adeno‐Associated Virus–Based Gene Therapy
Sun, K., & Liao, M. Z. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2141 · Cited by 37
Peptide‐Oligonucleotide Nanohybrids Designed for Precise Gene Therapy of Rheumatoid Arthritis
Wang, Q., Peng, X., Gao, X., Qin, Y., Li, W., Wu, Z., Lao, Z., Gao, A., Mao, Z., Xu, Y., et al. (2025) · Advanced Materials · doi:10.1002/adma.202500883 · Cited by 39
Peeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 33
Yin, L., Keeler, G. D., Zhang, Y., Hoffman, B. E., Ling, C., Qing, K., & Srivastava, A. (2020) · Gene Therapy · doi:10.1038/s41434-020-0140-1 · Cited by 30
Gene Doping and Genomic Science in Sports: Where Are We?
López, S., de Meirelles, J. L., Rayol, V., Poralla, G., Woldmar, N., Fadel, B., Figueiredo, M., Padilha, M. C., Neto, F. R. D. A., Pereira, H. M. G., et al. (2020) · Bioanalysis · doi:10.4155/bio-2020-0093 · Cited by 34
Wijaya, K. P., Ganegoda, N. C., Jayathunga, Y., Götz, T., Böck, W., Schäfer, M., & Heidrich, P. (2021) · Journal of Mathematics in Industry · doi:10.1186/s13362-020-00097-x · Cited by 31
Goodman, C. S., Berntorp, E. E., & Wong, O. (2022) · Haemophilia · doi:10.1111/hae.14425 · Cited by 32
Gene Therapy and Hemophilia: Where Do We Go from Here?
Bolous, N. S., Bhatt, N., Bhakta, N. H., Neufeld, E. J., Davidoff, A. M., & Reiss, U. M. (2022) · Journal of Blood Medicine · doi:10.2147/jbm.s371438 · Cited by 34
Hemophilia gene therapy: first, do no harm
Valentino, L. A., Kaczmarek, R., Pierce, G. F., Noone, D., O’Mahony, B., Page, D., Rotellini, D., & Skinner, M. W. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.06.016 · Cited by 30
Self-citationA primer to gene therapy: Progress, prospects, and problems
Zittersteijn, H. A., Gonçalves, M. A. F. V., & Hoeben, R. C. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12270 · Cited by 30
Hart, D. P., Branchford, B. R., Hendry, S., Ledniczky, R., Sidonio, R. F., Négrier, C., Kim, M. H., Rice, M., Minshall, M., Arcé, C., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01555-w · Cited by 29
Liver-Directed Adeno-Associated Virus–Mediated Gene Therapy for Mucopolysaccharidosis Type VI
Brunetti‐Pierri, N., Ferla, R., Ginocchio, V. M., Rossi, A., Fecarotta, S., Romanò, R., Parenti, G., Yıldız, Y., Zancan, S., Pecorella, V., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200052 · Cited by 30
Nathwani, A. C., McIntosh, J., & Sheridan, R. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.169 · Cited by 31
Gene therapy for hemophilia—opportunities and risks
Miesbach, W., Klamroth, R., Oldenburg, J., & Tiede, A. (2022) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2022.0353 · Cited by 47
Leveraging rAAV bioprocess understanding and next generation bioanalytics development
Escandell, J. M., Pais, D. A. M., Carvalho, S. B., Vincent, K. A., Gomes‐Alves, P., & Alves, P. M. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.12.009 · Cited by 32
SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders
Cnossen, M. H., van Moort, I., Reitsma, S. H., de Maat, M. P. M., Schutgens, R. E. G., Urbanus, R. T., Lingsma, H. F., Mathôt, R. A. A., Gouw, S. C., Meijer, K., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15778 · Cited by 28
The Arrival of Gene Therapy for Patients with Hemophilia A
Castaman, G., Minno, G. D., CRISTOFARO, R. D., & Peyvandi, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810228 · Cited by 34
Prime editing: current advances and therapeutic opportunities in human diseases
Fu, Y., He, X., Gao, X. D., Li, F., Ge, S., Yang, Z. H., & Fan, X. (2023) · 中国科学通报:英文版 · doi:10.1016/j.scib.2023.11.015 · Cited by 32
Long, B. R., Robinson, T. M., Day, J. R., Yu, H., Lau, K., Imtiaz, U., Patton, K. S., de Hart, G., Henshaw, J., Agarwal, S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.033 · Cited by 31
Spitz, S. M., Zhang, Y., Fischer, S. K., McGuire, K., Sommer, U., Amaravadi, L. S., Bandukwala, A., Eck, S., Garofolo, F., Islam, M. R., et al. (2021) · Bioanalysis · doi:10.4155/bio-2021-0005 · Cited by 36
Bosma, P. J., Wits, M., & Elferink, R. P. J. O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010273 · Cited by 28
Directed evolution of adeno-associated virus 5 capsid enables specific liver tropism
Wang, Y., Yang, C., Hu, H., Chen, C., Yan, M., Ling, F., Wang, K. C., Wang, X., Deng, Z., Zhou, X., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.017 · Cited by 27
Hemophilia gene therapy—New country initiatives
Reiss, U. M., Zhang, L., & Ohmori, T. (2020) · Haemophilia · doi:10.1111/hae.14080 · Cited by 54
Hemophilia: A Review of Perioperative Management for Cardiac Surgery
Kwak, J., Mazzeffi, M. A., Boggio, L. N., Simpson, M. L., & Tanaka, K. A. (2020) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2020.09.118 · Cited by 29
Gene Therapy for Inherited Bleeding Disorders
Arruda, V. R., Weber, J., & Samelson‐Jones, B. J. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1722862 · Cited by 25
Wang, L., Muthuramu, I., Somanathan, S., Zhang, H., Bell, P. L., He, Z., Yu, H., Zhu, Y., Tretiakova, A. P., & Wilson, J. M. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.017 · Cited by 28
Hemophilia A (Factor VIII Deficiency)
Seaman, C. D., Xavier, F., & Ragni, M. V. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.07.006 · Cited by 25
Comisel, R.-M., Kara, B., Fiesser, F. H., & Farid, S. S. (2021) · Biochemical Engineering Journal · doi:10.1016/j.bej.2021.108202 · Cited by 28
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations
Garrison, L. P., Pezalla, E., Towse, A., Yang, H., Faust, E., Wu, E. Q., Li, N., Sawyer, E. K., & Recht, M. (2021) · Value in Health · doi:10.1016/j.jval.2021.05.008 · Cited by 27
Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications
Luo, L., Zheng, Q., Chen, Z., Huang, M., Fu, L., Hu, J., Shi, Q., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019275 · Cited by 31
Kerpel‐Fronius, S., Baroutsou, V., Becker, S., Carlesi, R. M., Collia, L., Franke-Bray, B., Kleist, P., Kurihara, C., Laranjeira, L. F., Matsuyama, K., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.608249 · Cited by 29
The COVID‐19 pandemic: New global challenges for the haemophilia community
Hermans, C. R. J. R., Weill, A., & Pierce, G. F. (2020) · Haemophilia · doi:10.1111/hae.14001 · Cited by 25
Self-citationRecent developments of automated flow chemistry in pharmaceutical compounds synthesis
Wu, J., Yang, X., Pan, Y., Zuo, T., Ning, Z., Li, C., & Zhang, Z. (2023) · Journal of Flow Chemistry · doi:10.1007/s41981-023-00285-x · Cited by 28
Mahlangu, J. N., Jiménez‐Yuste, V., Ventriglia, G., Niggli, M., Barlera, S., Hermans, C. R. J. R., Lehle, M., Chowdary, P., Jew, L., Windyga, J., et al. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102364 · Cited by 24
Deshpande, S., Joseph, K., Tong, J., Chen, Y., Pishko, A. M., & Cuker, A. C. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014111 · Cited by 27
Gene therapy for hemophilia: Current status and laboratory consequences
Batty, P. A., & Lillicrap, D. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13605 · Cited by 27
Lisjak, M., Caneva, A. D., Marais, T., Barbon, E., Biferi, M. G., Porro, F., Barzel, A., Zentilin, L., Kay, M. A., Mingozzi, F., et al. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.785698 · Cited by 25
New directions to develop therapies for people with hemophilia
Gogia, P., Tarantino, M. D., Schramm, W., & Aledort, L. M. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2184341 · Cited by 25
Baatartsogt, N., Kashiwakura, Y., Hayakawa, M., Kamoshita, N., Hiramoto, T., Mizukami, H., & Ohmori, T. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.004 · Cited by 24
Wang, L., Warzecha, C. C., Kistner, A., Chichester, J. A., Bell, P. L., Buza, E. L., He, Z., Pampena, M. B., Couthouis, J., Sethi, S., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.007 · Cited by 26
Zhang, X., Chai, Z., Lee Dobbins, A., Itano, M. S., Askew, C., Miao, Z., Niu, H., Samulski, R. J., & Li, C. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121340 · Cited by 23
Akyüz, E., Aslan, F. Ş., Gokce, E., Ilmaz, O., Topcu, F., & Kakac, S. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16541 · Cited by 25
Inner Ear Gene Therapy: An Overview from Bench to Bedside
Gadenstaetter, A. J., Krumpoeck, P. E., & Landegger, L. D. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00759-1 · Cited by 24
Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?
Pierce, G. F., Kaczmarek, R., Noone, D., O’Mahony, B., Page, D., & Skinner, M. W. (2020) · Haemophilia · doi:10.1111/hae.14131 · Cited by 24
Self-citationSu, W., Sun, S., Tian, B., Tai, P. W. L., Luo, Y., Ko, J., Zhan, W., Xiao, K., Zheng, Q., Li, X., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.007 · Cited by 25
Vrouwe, J. P. M., Meulenberg, J. J. M., Klarenbeek, N. B., Navas-Cañete, A., Reijnierse, M., Ruiterkamp, G., Bevaart, L., Lamers, R. J., Kloppenburg, M., Nelissen, R. G. H. H., et al. (2021) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2021.09.013 · Cited by 29
Hakui, H., Kioka, H., Miyashita, Y., Nishimura, S., Matsuoka, K., Kato, H., Tsukamoto, O., Kuramoto, Y., Takuwa, A., Takahashi, Y., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abf3274 · Cited by 23
Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A
ten Ham, R. M. T., Walker, S. M., Soares, M. O., Frederix, G., Leebeek, F. W. G., Fischer, K., Coppens, M., & Palmer, S. J. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000679 · Cited by 23
Cellular stress and coagulation factor production: when more is not necessarily better
Chen, Z., Herzog, R. W., & Kaufman, R. J. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.10.005 · Cited by 25
Hemophilia gene therapy: ushering in a new treatment paradigm?
George, L. A. (2021) · Hematology · doi:10.1182/hematology.2021000254 · Cited by 25
Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies
Ito, M., Takino, N., Nomura, T., Kan, A., & Muramatsu, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-88614-9 · Cited by 23
Gardin, A., & Ronzitti, G. (2023) · Archives de Pédiatrie · doi:10.1016/s0929-693x(23)00227-0 · Cited by 25
Quinn, J., Delaney, K. A., Wong, W. Y., Miesbach, W., & Bullinger, M. (2022) · Patient Related Outcome Measures · doi:10.2147/prom.s357555 · Cited by 21
Self-citationBaatartsogt, N., Kashiwakura, Y., Hiramoto, T., Hayakawa, M., Kamoshita, N., & Ohmori, T. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3505 · Cited by 23
RNAi for the Treatment of People with Hemophilia: Current Evidence and Patient Selection
Boyce, S., & Rangarajan, S. (2023) · Journal of Blood Medicine · doi:10.2147/jbm.s390521 · Cited by 22
Self-citationKavita, U., Sun, K., Braun, M., Lembke, W., Mody, H. R., Kamerud, J., Yang, T., Braun, I. V., Fang, X., Gao, W., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00842-1 · Cited by 23
Du, X., Zhao, M., Jiang, L., Pang, L., Wang, J., Lv, Y., Yao, C., & Wu, R. (2024) · Drug Delivery · doi:10.1080/10717544.2024.2306231 · Cited by 22
Gene Therapy for Monogenic Inherited Disorders: Opportunities and Challenges
Kirschner, J., & Cathomen, T. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0878 · Cited by 33
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY
Doshi, B. S., Arruda, V. R., & Arruda, V. R. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.069 · Cited by 25
Tratamiento de la hemofilia: de la terapia sustitutiva a la terapia génica
Páramo, J. A. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.04.031 · Cited by 23
Ozelo, M. C., Mason, J. A., Dunn, A. L., Villaça, P. R., Shen, M., Agarwal, S., Imtiaz, U., Liu, H., & Robinson, T. M. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.12.038 · Cited by 21
Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency
Cao, W., Dong, B., Horling, F., Firrman, J., Lengler, J., Klugmann, M., de la Rosa, M., Wu, W., Qizhao, W., Wei, H., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.013 · Cited by 21
CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia A
Luo, S., Li, Z., Dai, X., Zhang, R., Liang, Z., Li, W., Zeng, M., Su, J., Wang, J., Liang, X., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.672564 · Cited by 22
The intersection of vector biology, gene therapy, and hemophilia
Lisowski, L., Staber, J. M. R., Wright, J. F., & Valentino, L. A. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12586 · Cited by 19
Chen, M., Kim, B., Jarvis, M., Fleury, S., Deng, S., Nouraein, S., Butler, S. S., Lee, S., Chambers, C., Hodges, H. C., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00371-0 · Cited by 20
Sternberg, A. R., Martos-Rus, C., Davidson, R. J., Liu, X., & George, L. A. (2024) · Nature Communications · doi:10.1038/s41467-024-51296-8 · Cited by 24
Encouraging and Unsettling Findings in Long-Term Follow-up of AAV Gene Transfer
Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.007 · Cited by 18
“A 3-year follow-up of hepatic gene transfer, following intravenous high-dose delivery of a serotype 5 vector expressing factor VIII, has been encouraging.(3) At 6 10(13) vector genomes/kg, average FVIII activity levels were in the normal rage.”
BackgroundNon-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials
Tiwade, P. B., Fung, V., VanKeulen‐Miller, R., Narasipura, E. A., Ma, Y., & Fenton, O. S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00871 · Cited by 21
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials
Xue, F., Ju, M., Zhu, T., Zhou, Z., Sun, J., Yang, L., Yan, Z., Zhou, H., Du, X., Zheng, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04012-y · Cited by 23
Chai, Z., Zhang, X., Dobbins, A. L., Samulski, R. J., Merricks, E. P., Nichols, T. C., & Li, C. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.083 · Cited by 19
Astermark, J., Blatný, J., Königs, C., Hermans, C. R. J. R., Jiménez‐Yuste, V., & Hart, D. P. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231165857 · Cited by 18
Clinical pharmacology of emicizumab for the treatment of hemophilia A
Yoneyama, K., Schmitt, C., Portron, A., Kiialainen, A., Kotani, N., Jaminion, F., Retout, S., & Adamkewicz, J. I. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2243213 · Cited by 24
Han, J. P., Lee, Y., Lee, J. H., Chung, H. Y., Lee, G. S., Nam, Y. R., Choi, M., Moon, K., Lee, H., Lee, H., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102050 · Cited by 19
Pierce, G. F., Pasi, J., Coffin, D., Kaczmarek, R., Lillicrap, D., Mahlangu, J. N., Rotellini, D., Sannié, T., Srivastava, A., VandenDriessche, T., et al. (2020) · Haemophilia · doi:10.1111/hae.13971 · Cited by 18
Self-citationThe critical need for postmarketing surveillance in gene therapy for haemophilia
Konkle, B. A., Recht, M., Hilger, A., & Marks, P. W. (2020) · Haemophilia · doi:10.1111/hae.13972 · Cited by 20
Aradom, E., & Gomez, K. (2021) · The Journal of Haemophilia Practice · doi:10.17225/jhp00174 · Cited by 20
Management of haemophilia A with inhibitors: A regional cross‐talk
Peyvandi, F., Kavaklı, K., El-Beshlawy, A. M., & Rangarajan, S. (2022) · Haemophilia · doi:10.1111/hae.14638 · Cited by 21
Self-citationThe WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025
Pierce, G. F., Ozelo, M. C., Mahlangu, J. N., Dunn, A. L., Beijlevelt, M., Bender, R., Carcao, M. D., Coffin, D., Grazzi, E. F., Foster, G. R., et al. (2025) · Haemophilia · doi:10.1111/hae.70113 · Cited by 24
Self-citationRecent advances in upstream process development for production of recombinant adeno‐associated virus
Ou, J., Tang, Y., Xu, J., Tucci, J., Borys, M., & Khetan, A. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28545 · Cited by 18
Liu, M., Wang, L., Li, Y., Zhi, E., Shen, G., Jiang, X., Li, D., Zhao, X., Ruan, T., Jiang, C., et al. (2024) · Advanced Science · doi:10.1002/advs.202402412 · Cited by 18
Structural characterization of a bat Adeno-associated virus capsid
Mietzsch, M., Li, Y., Kurian, J. J., Smith, J. K., Chipman, P. R., McKENNA, R. V., Yang, L., & Agbandje‐McKenna, M. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2020.107547 · Cited by 18
Vasquez-Loarte, T. C., Lucas, T. L., Harris-Wai, J. N., & Bowen, D. J. (2020) · Patient · doi:10.1007/s40271-020-00442-7 · Cited by 17
Patient selection for hemophilia gene therapy: Real‐life data from a single center
Krumb, E., Lambert, C., & Hermans, C. R. J. R. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12494 · Cited by 17
Preclinical Assessment of a Gene Editing Approach in a Mouse Model of MNGIE
Parés, M., Fornaguera, C., Vila‐Julià, F., Oh, S., Fan, S. H. Y., Tam, Y. K., Comes, N., Vidal, F., Martí, R., Borrós, S., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.152 · Cited by 20
Hemophilia A Gene Therapy — Some Answers, More Questions
George, L. A. (2023) · New England Journal of Medicine · doi:10.1056/nejme2212347 · Cited by 17
A comprehensive study of AAV tropism across C57BL/6 mice, BALB/c mice, and crab-eating macaques
Fang, K., Yang, X., Liu, Y., Xia, J., Wu, R., Yang, F., Feng, C., Liu, X., Shi, L., Geng, G., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101434 · Cited by 17
Biosafety Practices for In Vivo Viral-Mediated Gene Therapy in the Health Care Setting
Blind, J. E., McLeod, E. N., Brown, A. M., Patel, H., & Ghosh, S. (2020) · Applied Biosafety · doi:10.1177/1535676020942195 · Cited by 17
Metadata
- Authors
- Pasi, K. J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C. B., Li, M., Pierce, G. F., & Wong, W. Y.
- Affiliations
- From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy’s and St. Thomas’ NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) — all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private...
- University Hospitals Birmingham NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-02
- Volume
- 382
- Issue
- 1
- Pages
- 29-40
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2998050720
- Cited by
- 448
- References
- 29
- Citations by year
- 2026: 30 · 2025: 52 · 2024: 59 · 2023: 67 · 2022: 96 · 2021: 71 · 2020: 73
- FWCI
- 48.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- BioMarin Pharmaceutical
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hemophilia A, adeno-associated virus gene therapy, factor VIII, long-term safety, annualized bleeding rate, transgene expression kinetics
- MeSH terms
- Dependovirus, Adult, Coagulants, Factor VIII, Follow-Up Studies, Genetic Vectors, Hemophilia A, Hemorrhage, Humans, Infusions, Intravenous, Male, Middle Aged, Genetic Therapy, Biomarkers, Transgenes, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.